These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10941249)

  • 1. [Economic criteria for covering medical interventions by the German Public Health Insurance].
    Grell L
    Med Klin (Munich); 2000 Jun; 95 Suppl 1():18-20. PubMed ID: 10941249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public health policy decisions on medical innovations: what role can early economic evaluation play?
    Hartz S; John J
    Health Policy; 2009 Feb; 89(2):184-92. PubMed ID: 18619704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rationing in German health care with particular consideration of oncology: view points of German stakeholders--a qualitative interview study].
    Lange J; Gönner C; Vollmann J; Rauprich O
    Gesundheitswesen; 2015 Jan; 77(1):8-15. PubMed ID: 24696371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
    Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
    Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health policy uses and usefulness of cost-benefit and cost-effectiveness analysis.
    Warner KE
    Mead Johnson Symp Perinat Dev Med; 1982; (20):53-69. PubMed ID: 6821470
    [No Abstract]   [Full Text] [Related]  

  • 7. [Guidelines for health-economic evaluations in Austria].
    Walter E; Zehetmayr S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):628-32. PubMed ID: 17211768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OMERACT: economic evaluations and health policy.
    Ruff B
    J Rheumatol; 2001 Mar; 28(3):666-9. PubMed ID: 11296979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A strategic plan for integrating cost-effectiveness analysis into the US healthcare system.
    Neumann PJ; Palmer JA; Daniels N; Quigley K; Gold MR; Chao S;
    Am J Manag Care; 2008 Apr; 14(4):185-8. PubMed ID: 18402510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The growing role of chiropractic in health care delivery.
    Stano M; Ehrhart J; Allenburg TJ
    J Am Health Policy; 1992; 2(6):39-45. PubMed ID: 10122418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [What must now be addressed in health policy].
    Braun LG; Gürkan I; Jacobs P; Räsch RJ; Walter N
    Chirurg; 2003 Feb; 74(2):M41-4. PubMed ID: 12691061
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness and evidence evaluation as criteria for coverage policy.
    Garber AM
    Health Aff (Millwood); 2004; Suppl Web Exclusives():W4-284-96. PubMed ID: 15451997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The challenges of economic evaluations of remote technical health interventions.
    Kennedy CA
    Clin Invest Med; 2005 Apr; 28(2):71-4. PubMed ID: 15909483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The economic analysis of prevention: an illustration involving children's behavior problems.
    Foster EM; Jones DE
    J Ment Health Policy Econ; 2007 Dec; 10(4):165-75. PubMed ID: 18166828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of waiting time on cost-effectiveness.
    Koopmanschap MA; Brouwer WB; Hakkaart-van Roijen L; van Exel NJ
    Soc Sci Med; 2005 Jun; 60(11):2501-4. PubMed ID: 15814175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost of psoriasis.
    Crown WH
    Manag Care; 2003 May; 12(5 Suppl):10-3; discussion 20-1. PubMed ID: 18564553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why Medicare has not established criteria for coverage decisions.
    Tunis SR
    N Engl J Med; 2004 May; 350(21):2196-8. PubMed ID: 15152066
    [No Abstract]   [Full Text] [Related]  

  • 18. Controlling health care costs in Massachusetts after health care reform: there is no silver bullet.
    Bigby J
    Arch Intern Med; 2009 Nov; 169(20):1833-5. PubMed ID: 19901133
    [No Abstract]   [Full Text] [Related]  

  • 19. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How do economic evaluations inform health policy decisions for treatment and prevention in Canada and the United States?
    Husereau D; Culyer AJ; Neumann P; Jacobs P
    Appl Health Econ Health Policy; 2015 Jun; 13(3):273-9. PubMed ID: 25316309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.